<DOC>
	<DOCNO>NCT00322439</DOCNO>
	<brief_summary>This observational safety study track psoriasis patient etanercept ( Enbrel ) 5 year .</brief_summary>
	<brief_title>Observational Safety Study Etanercept ( Enbrel ) Treatment Psoriasis</brief_title>
	<detailed_description>This prospective , multi-center , observational surveillance registry evaluate data long-term safety etanercept ( Enbrel ) use treatment psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients plaque psoriasis Prior exposure tumor necrosis factor ( TNF ) inhibitor Patients Enbrel contraindicate Patients currently enrol yet complete least 30 day since end investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>plaque Psoriasis patient</keyword>
	<keyword>TNF-inhibitor na√Øve</keyword>
</DOC>